List of largest selling pharmaceutical products
Drugs with sales above $5 billion in 2015 included:[1]
Largest selling pharmaceutical products
Rank | Drug | Trade name | Type | Main indications | Company | Sales (USD millions/year) | ∆ vs 2014 |
---|---|---|---|---|---|---|---|
1 | Adalimumab | Humira | Biologic | Rheumatoid arthritis | AbbVie Inc. | 14,012 | 1,469 |
2 | Ledipasvir/sofosbuvir | Harvoni | Small molecule | Hepatitis C | Gilead Sciences | 13,864 | 11,737 |
3 | Etanercept | Enbrel | Biologic | Rheumatoid arthritis | Amgen | 8,697 | 4,009 |
4 | Infliximab | Remicade | Biologic | Crohn's Disease Rheumatoid Arthritis |
Johnson & Johnson | 8,355 | 1,487 |
5 | Rituximab | Mabthera
Rituxan |
Biologic | Lymphoma | Roche | 7,115 | 1,456 |
6 | Insulin glargine | Lantus | Biologic | Diabetes mellitus | Sanofi | 7,029 | 51 |
7 | Bevacizumab | Avastin | Biologic | Metastatic cancers | Roche | 6,751 | 270 |
8 | Trastuzumab | Herceptin | Biologic | Breast cancer | Roche | 6,603 | 265 |
9 | Lenalidomide | Revlimid | Small molecule | Multiple myeloma | Celgene | 5,801 | 821 |
10 | Sofosbuvir | Sovaldi | Small molecule | Hepatitis C | Gilead Sciences | 5,276 | (5,007) |
11 | Fluticasone propionate/salmeterol | Seretide
Advair |
Small molecule | Asthma | GlaxoSmithKline | 5,227 | (778) |
12 | Rosuvastatin | Crestor | Small molecule | Cardiovascular diseases | AstraZeneca | 5,017 | (495) |
For the fourth quarter of 2013, the largest selling drugs were:[2]
Rank | Brand Name(s) | Generic Name | Sales Q1 2014 Sales ($000) | Change from Q4 2013 | Company(ies) | Disease/Medical Use | First Approval Date | Patent Expiration Date[3][4] |
---|---|---|---|---|---|---|---|---|
1 | Abilify | Aripiprazole | 1,602,329 | 2.23% | Generic | Psychosis; depression | Nov-2002 | 2014-Oct |
2 | Humira | Adalimumab | 1,561,861 | 3.86% | AbbVie | Crohn's disease; Rheumatoid arthritis | Dec-2002 | 2016-Dec |
3 | Nexium | Esomeprazole | 1,536,435 | 0.74% | Generic | Gastrointestinal disorders | Mar-2000 | 2014-May |
4 | Crestor | Rosuvastatin | 1,333,502 | 4.53% | AstraZeneca, Shionogi | Cholesterol | Nov-2002 | 2016-Jul |
5 | Enbrel | Etanercept | 1,189,844 | 1.46% | Amgen | Rheumatoid arthritis | Nov-1998 | 2012-Oct |
6 | Advair Diskus, Seretide | Fluticasone/salmeterol | 1,147,330 | 2.65% | GlaxoSmithKline | Asthma | Aug-2000 | 2012-Mar |
8 | Remicade | Infliximab | 994,020 | -2.71% | Centocor Ortho Biotech, Inc., Mitsubishi Tanabe Pharma | Crohn's disease; rheumatoid arthritis | Aug-1998 | n/a |
9 | Lantus Solostar | Insulin glargine | 939,691 | 9.39% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | 2011-Dec |
10 | Neulasta | Filgrastim | 854,508 | -4.90% | Amgen | Neutropenia | Jan-2002 | Mon-20XX |
11 | Copaxone | Glatiramer | 851,351 | -4.69% | Generic | Multiple sclerosis | Dec-1996 | Nov-2014 |
12 | Rituxan, MabThera | Rituximab | 746,766 | -0.16% | Biogen Idec, Chugai Pharmaceutical, Genentech/Roche | Non-Hodgkin’s lymphoma; rheumatoid arthritis | Nov-1997 | Mon-20XX |
13 | Spiriva | Tiotropium bromide | 726,057 | 3.39% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Apr-2002 | 2018-Jul |
14 | Januvia | Sitagliptin | 700,941 | 3.63% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1996 | 2017-Nov |
15 | Lantus | Insulin glargine | 685,461 | 5.84% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | Dec-2011 |
16 | Atripla | Emtricitabine/tenofovir/efavirenz | 679,418 | 0.36% | Gilead Sciences, Inc. | HIV infection | Dec-1996 | Mar-2015 |
17 | Cymbalta | Duloxetine | 664,186 | -23.06% | Generic | Depression; anxiety disorders | Aug-2004 | Dec-2013 |
18 | Avastin | Bevacizumab | 650,208 | -1.25% | Genentech/Roche | Cancer | Feb-2004 | Mon-20XX |
19 | Lyrica | Pregabalin | 624,774 | 2.82% | Pfizer | Neuropathic pain | Jul-2004 | Jul-2019 |
20 | OxyContin | Oxycodone | 585,482 | -2.91% | Generic | Pain | Dec-1996 | Mon-20XX |
21 | Celebrex | Celecoxib | 580,332 | 5.23% | Generic | Osteoarthritis; rheumatoid arthritis | Dec-1998 | May-2014 |
22 | Epogen | Epoetin alfa | 503,493 | -2.08% | Amgen | Anemia | Jun-1989 | Mon-20XX |
23 | Truvada | Tenofovir/emtricitabine | 542,846 | 0.03% | Gilead Sciences | HIV infection | Aug-2004 | Mon-20XX |
24 | Diovan | Valsartan | 533,924 | -2.80% | Generic | Hypertension | Dec-1996 | Sep-2012 |
25 | Levemir | Insulin detemir | 424,186 | 9.34% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Dec-1990 | Mon-20XX |
26 | Gleevec, Glivec | Imatinib | 498,149 | 7.22% | Novartis | Leukemia | May-2001 | Jan-2015 |
27 | Herceptin | Trastuzumab | 473,632 | 1.53% | Chugai Pharmaceutical, Genentech/Roche | Breast cancer | Sep-1998 | Mon-20XX |
28 | Vyvanse | Lisdexamfetamine | 447,188 | 9.39% | Shire | Attention deficit hyperactivity disorder | Dec-1990 | Mon-20XX |
29 | Lucentis | Ranibizumab | 460,621 | -0.84% | Genentech | Macular degeneration | Dec-1990 | Mon-20XX |
30 | Zetia | Ezetimibe | 444,731 | 4.04% | Merck & Co., Schering-Plough | Cholesterol | Oct-2002 | 2017-Oct |
31 | Combivent | Ipratropium bromide/salbutamol | 391,404 | 20.28% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
32 | Symbicort | Budesonide/formoterol | 407,646 | 9.63% | AstraZeneca | Asthma | Aug-2000 | Mon-20XX |
33 | Namenda | Memantine | 434,766 | -6.00% | Generic | Alzheimer's disease | Oct-2003 | Apr-2014 [5] |
34 | NovoLog FlexPen | Insulin aspart | 364,870 | 7.84% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
35 | Xarelto | Rivaroxaban | 321,462 | 18.72% | Bayer | Oral anticoagulant | Dec-1996 | Sep-2012 |
36 | NovoLog | Insulin aspart | 344,235 | 3.86% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
37 | Humalog | Insulin lispro | 304,866 | 6.15% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
38 | Suboxone | Buprenorphine | 321,892 | -2.11% | Reckitt Benckiser Pharmaceuticals Inc. | Pain; opioid addiction | Aug-2000 | Mon-20XX |
40 | Viagra | Sildenafil | 300,463 | 3.26% | Pfizer | Erectile dysfunction | Mar-1998 | Mar-2012 |
41 | Seroquel XR | Quetiapine | 291,494 | 2.22% | Generic | Psychosis; depression | Sep-1997 | Mar-2012 |
33 | ONE TOUCH ULTRA | Telaprevir | 370,899 | 0.00% | Johnson & Johnson | Hepatitis C | Dec-1990 | Mon-20XX |
35 | AndroGel | Testosterone gel | 351,737 | 5.47% | Generic | Low testosterone levels | Oct-2002 | Oct-2016 |
37 | Enoxaparin | Enoxaparin | 341,184 | 6.55% | Generic | Deep-vein thrombosis | Mar-1993 | 2012-Aug |
38 | Ritalin | Methylphenidate | 327,346 | 2.26% | Generic | Attention deficit hyperactivity disorder | Aug-2000 | Mon-20XX |
41 | ProAir HFA | Salbutamol | 306,461 | 10.87% | Teva Pharmaceuticals | Asthma; chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
43 | Alimta | Pemetrexed | 302,728 | 6.00% | Eli Lilly and Company | Cancer | Feb-2004 | Mon-20XX |
44 | Victoza | Liraglutide | 301,414 | 9.59% | Novo Nordisk | Diabetes mellitus type 2 | May-1909 | Mon-20XX |
47 | Synagis | Palivizumab | 289,704 | 0.00% | MedImmune | RSV infection | Feb-1998 | Aug-2012 |
48 | Avonex | Interferon beta 1a | 281,554 | -1.43% | Biogen Idec | Multiple sclerosis | May-1996 | Mon-20XX |
49 | Renvela | Sevelamer | 280,917 | 21.44% | Generic | Hyperphosphatemia | Apr-2002 | Apr-2016 [6] |
50 | Rebif | Interferon beta 1a | 280,548 | -6.27% | Serono | Multiple sclerosis | Feb-1998 | Mon-20XX |
51 | Cialis | Tadalafil | 280,518 | 4.58% | Eli Lilly and Company, Lilly Icos | Erectile dysfunction | Nov-2002 | 2017-Nov |
52 | Gilenya | fingolimod | 272,701 | 4.05% | Novartis Corporation | Multiple sclerosis | Feb-2000 | 2007-Jan |
53 | Nasonex | Mometasone | 272,345 | 5.67% | Schering-Plough | Allergic rhinitis | Oct-1997 | 2018-Oct |
54 | Stelara | Ustekinumab | 270,598 | 12.47% | Johnson & Johnson | Psoriasis; psoriatic arthritis | Apr-2000 | Mon-20XX |
55 | Restasis | Ciclosporin ophthalmic emulsion | 268,463 | 6.30% | Allergan, Inc, Lilly Icos | Dry eye syndrome | Nov-2002 | Mon-20XX |
56 | Budesonide | Budesonide | 268,201 | 26.81% | Generic | Asthma | Aug-2000 | Mon-20XX |
57 | Acetaminophen/hydrocodone | Acetaminophen/hydrocodone | 264,814 | 6.67% | Generic | Pain | Aug-2000 | Mon-20XX |
58 | Flovent HFA | Fluticasone propionate | 263,072 | 13.97% | GlaxoSmithKline | Asthma | Mar-1996 | Mon-20XX |
59 | Lovaza | Omega-3 fatty acid ethyl esters | 258,177 | 2.90% | GlaxoSmithKline | Cholesterol | Jun-2001 | Mon-20XX |
60 | Prezista | Darunavir | 251,372 | 3.54% | Johnson & Johnson | HIV infection | Jun-2006 | Mon-20XX |
61 | Isentress | Raltegravir | 248,924 | 0.72% | Merck & Co., Inc. | HIV Infection | Dec-1998 | Mon-20XX |
62 | Janumet | Sitagliptin/metformin | 247,150 | 4.65% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1998 | Mon-20XX |
63 | Procrit, Eprex | Epoetin alfa | 241,535 | -10.09% | Johnson & Johnson | Anemia | Dec-1990 | Mon-20XX |
64 | Doxycycline | Doxycycline | 241,381 | -5.65% | Generic | Bacterial infections | Dec-1996 | Nov-2011 |
65 | Orencia | Abatacept | 241,149 | 1.65% | Bristol-Myers Squibb Company | Rheumatoid arthritis | Aug-2000 | Mon-20XX |
66 | Amphetamine/dextroamphetamine | Amphetamine mixed salts | 240,482 | 2.78% | Generic | Attention deficit hyperactivity disorder; narcolepsy | Feb-2004 | Mon-20XX |
67 | Vesicare | Solifenacin | 240,435 | 5.37% | Astellas Pharma US | Overactive bladder | Feb-2000 | 2018-Nov |
68 | Dexilant | Dexlansoprazole | 238,897 | 7.57% | Takeda Pharmaceuticals North America, Inc | Gastrointestinal disorders | Dec-2004 | Jul-2012 |
69 | Humalog KwikPen | Insulin lispro | 238,418 | 11.02% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
70 | Neupogen | Filgrastim | 229,912 | -2.70% | Amgen | Neutropenia | Feb-1991 | Mon-20XX |
71 | Lidocaine | Lidocaine | 225,903 | 0.00% | Generic | Pain | Mar-1999 | Mon-20XX |
72 | Lunesta | Eszopiclone | 225,101 | 5.24% | Generic | Insomnia | Dec-2004 | April-2015 |
73 | Fenofibrate | Fenofibrate | 223,300 | -2.22% | Generic | Cholesterol | Feb-1998 | Mon-20XX |
74 | Zytiga | Abiraterone | 222,026 | 11.86% | Janssen Biotech, Inc. | Prostate Cancer | Dec-1998 | April-2015 |
75 | Reyataz | Atazanavir | 217,793 | -1.38% | Bristol-Myers Squibb | HIV infection | Jan-2003 | Mon-20XX |
76 | Sensipar | Cinacalcet | 216,657 | 13.71% | Amgen Inc. | Hyperparathyroidism | Apr-2000 | Mon-20XX |
77 | Metoprolol | Metoprolol | 215,111 | 2.99% | Generic | Hypertension | Jan-1992 | Mon-20XX |
78 | AcipHex | Rabeprazole | 214,251 | 10.03% | Janssen Pharmaceuticals, Inc, Johnson & Johnson | Gastrointestinal disorders | Aug-1999 | Nov-2013 |
79 | Synthroid | Levothyroxine | 213,424 | -2.50% | Generic | Hypothyroidism | May-1999 | Expired |
80 | Avonex Pen | Olmesartan | 211,917 | 13.59% | Biogen Idec, Forest Laboratories | Hypertension | Apr-2002 | Apr-2016 |
81 | Prevnar 13 | Pneumococcal conjugate vaccine | 209,367 | 6.41% | Pfizer | Pneumococcal disease | Feb-2000 | Jan-2007 |
82 | Xolair | Omalizumab | 207,891 | 1.91% | Genentech, Novartis | Asthma | 2003 | Mon-20XX |
83 | Lipitor | Atorvastatin | 207,542 | 4.23% | Generic | Cholesterol | Dec-1996 | Nov-2011 [7] |
84 | levothyroxine | Levothyroxine | 204,755 | 0.00% | Generic | Hypothyroidism | Aug-1990 | Mon-20XX |
85 | Benicar | Olmesartan/hydrochlorothiazide | 203,336 | 3.22% | Daiichi Sankyo | Hypertension | Jun-1909 | Mon-2016 |
86 | Stribild | Elvitegravir/cobicistat/emtricitabine/tenofovir | 202,642 | 0.00% | Gilead Sciences | HIV/AIDS | Apr-2000 | Mon-20XX[8] |
87 | Zostavax | Zostavax | 202,240 | 15.17% | Eisai, Merck & Co. | Herpes zoster | Aug-1999 | May-2013 |
88 | Pradaxa | Dabigatran | 200,697 | -0.53% | Boehringer Ingelheim, Lilly Icos | Oral anticoagulant | Oct-2010 | Mon-20XX |
89 | Vytorin | Ezetimibe/simvastatin | 199,625 | -3.02% | Merck & Co., Schering-Plough | Cholesterol | Jul-2004 | Mon-20XX |
90 | Tamiflu | Oseltamivir | 197,718 | 0.00% | Chugai Pharmaceutical, Hetero Drugs, Roche | Influenza | Oct-1999 | Mon-20XX |
91 | Xgeva | Denosumab | 197,711 | 3.24% | Amgen | Osteoporosis | Nov-2010 | Mon-20XX |
92 | Evista | Raloxifene | 196,929 | -4.31% | Eli Lilly and Company, Chugai Pharmaceutical | Osteoporosis | Dec-1997 | Jan-2013 |
93 | Xeloda | Capecitabine | 194,044 | 6.52% | Generic | Cancer | Jun-1909 | Mon-20XX [9] |
94 | Aranesp | Darbepoetin alfa | 185,225 | -9.22% | Amgen Inc. | Anemia | Jun-2001 | Mon-20XX |
95 | Ventolin HFA | Salbutamol | 183,060 | 0.00% | GlaxoSmithKline | Asthma; chronic obstructive pulmonary disease | May-1981 | Mon-20XX |
96 | divalproex sodium | Valproate | 181,554 | 0.00% | Generic | Gastrointestinal disorders | Jun-1909 | Mon-20XX |
97 | Afinitor | Everolimus | 180,719 | 0.03% | Novartis | Cancer | Jun-1909 | Mon-20XX |
98 | Betaseron, Betaferon | Interferon beta 1b | 179,216 | -3.72% | Bayer | Multiple sclerosis | Jul-1993 | Mon-20XX |
99 | Adderall XR | Amphetamine mixed salts | 177,505 | 3.31% | Generic | Attention deficit hyperactivity disorder | Oct-2001 | Mon-20XX |
100 | Complera | Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate | 174,933 | 0.00% | Gilead Sciences, Inc. | HIV | Jun-20XX | Mon-20XX |
See also
References
- ↑ "Top drugs by sales revenue in 2015: Who sold the biggest blockbuster drugs?". March 10, 2016. Retrieved October 19, 2016.
- ↑ Drugs.com U.S. Pharmaceutical Sales - Q4 2013, updated Feb. 2014
- ↑ Patent Terms Extended Under 35 USC §156
- ↑ Orange Book Trade Name Search
- ↑ Unknown. "Generic Namenda Availability - Drugs.com". www.drugs.com. Drugs.com. Retrieved 21 December 2015.
- ↑ Donohue, Mark. "Impax Laboratories Inc. - Impax Launches Authorized Generic RENVELA®". investors.impaxlabs.com. Impax Laboratories. Retrieved 21 December 2015.
- ↑ "Atorvastatin: Drug Uses, Dosage, Side Effects - Drugs.com". www.drugs.com. drugs.com. Retrieved 21 December 2015.
- ↑ "HIV Treatment". www.stribild.com.
- ↑ Walsh, Sandy. "Press Announcements - FDA approves first generic capecitabine to treat colorectal and breast cancers". www.fda.gov. United States Food and Drug Administration. Retrieved 21 December 2015.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.